Clinical Trials
6 trialsNCT03525392 2023-12-12
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
Ipsen
Phase 1 Terminated
NCT03435640 2023-03-08
REVEAL
Nektar Therapeutics
Phase 1/2 Terminated
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT04099277 2021-08-31
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02452424 2020-03-05
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
Phase 1/2 Terminated
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed